Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation.
Aznab M et al. Asia Pac J Clin Oncol. 2015 Nov 4. doi: 10.1111/ajco.12418. [Epub ahead of print].

Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.
Hungria VT et al. Ann Hematol. 2015 Oct 30. [Epub ahead of print].

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F et al. Lancet Oncol. 2015 Nov 16. pii: S1470-2045(15)00389-7. doi: 10.1016/S1470-2045(15)00389-7. [Epub ahead of print].

Plerixafor for stem cell mobilization: the current status.
Bilgin YM et al. Curr Opin Hematol. 2015 Nov 7. [Epub ahead of print].

At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study.
Martínez-Cibrian N et al. Bone Marrow Transplant. 2015 Nov 23. doi: 10.1038/bmt.2015.287. [Epub ahead of print].

Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.
Cerchione C et al. Eur J Haematol. 2015 Nov 21. doi: 10.1111/ejh.12705. [Epub ahead of print]